+65.2%
ALAB vs MRNA
+511.3%
-446.1%
-60.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +9.8% | -2.2% | +12.0% | +9.8% |
| 7D | +7.2% | +5.5% | +1.8% | +7.2% |
| 30D | -2.5% | +158.7% | -161.3% | -6.1% |
| 3M | -13.3% | +182.1% | -195.4% | -18.5% |
| 6M | +172.8% | +151.8% | +21.0% | +160.0% |
| YTD | +86.6% | +393.6% | -307.0% | +54.8% |
| 1Y | +65.2% | +499.5% | -434.3% | +34.5% |
| All | +65.2% | +511.3% | -446.1% | +34.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling